viewSareum Holdings PLC

Sareum Holdings primed for progress


  • Lead drug being developed by partner Sierra Oncology
  • Encouraging preliminary efficacy data on SRA737 
  • Has other preclinical treatments - one autoimmune disease, one for cancer

Quick facts: Sareum Holdings PLC

Price: 0.685 GBX

Market: AIM
Market Cap: £21.04 m


We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.

Dr Tim Mitchell, chief executive


About Sareum

Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology

The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.



This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage

. It is currently undergoing two Phase II clinical trials in patients with advanced cancer – one as a monotherapy and another in combination with low-dose gemcitabine, which is one of the most commonly commonly-prescribed chemotherapies.

Preliminary efficacy data from a phase I/II clinical trial carried out by Vancouver-based Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties, was encouraging.  

Most eye-catching among the headlines was the impact SRA737 had in harness with gemcitabine in patients with anogenital cancer, where the response rate was 30%.



What else is in the pipeline

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation.


What the boss says: Tim Mitchell, CEO 

"We are very pleased with the progress of our proprietary dual TYK2/JAK1 programmes," Mitchell said in October. 

“We believe these offer a novel oral immunotherapy approach to addressing unmet needs in autoimmune diseases and cancer and that their mechanism is gaining increasing interest from the pharmaceutical industry.

"Mitchell also remains hopeful that partner Sierra Oncology will be able to find the funds to develop cancer treatment molecule SRA737, especially after encouraging clinical results in June and good indications from pre-clinical combinations with other therapies."


Inflexion points 

  • Commercial licences for the late pre-clinical or early clinical stages of SDC 1801/1802
  • Sierra Oncology raises funds for development of SRA737
  • Raised £780,000 in July



The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings new licensing deal 'could generate significant near-term...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell speaks to Proactive's Andrew Scott soon after announcing a licensing deal with an unnamed Chinese specialty pharmaceutical company. The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for...

on 31/3/20

2 min read